TAIPEI-EXCHANGE
8.6.2022 10:02:10 CEST | Business Wire | Press release
The Taipei Exchange (TPEx), has successfully built an efficient multi-tiered fund-raising platform to foster the growth of innovative companies within the Taiwan capital market while also focusing on Environmental, Social and Governance (ESG) practices.
Support for Innovation
Along with a Mainboard of well-established companies, TPEx provides an Emerging Stock market, which includes Emerging Stock board and Pioneer Stock board, for companies prior to IPO, and the Go Incubation Board for Startup and Acceleration Firms. This multi-tiered structure aims to support the growth of enterprises through various stages of their development.
In line with Taiwan government policies, TPEx has been devoted to fostering innovative industries, high-tech industries, and small and medium-sized enterprises (SMEs), thus driving the momentum of Taiwan’s economy. Since its establishment 28 years ago, TPEx has assisted more than 2,300 public companies to gain access and contribute to the Taiwan capital market.
Environmental, Social and Governance (ESG) Practices
While providing a convenient mechanism for fundraising, TPEx also assists listed companies in setting their sustainable operations and ESG practices in response to the impact of climate change and international attention to the sustainability issue. As The European Union’s (EU’s) proposed new directive on corporate sustainability reporting (CSRD) is planned to come into effect in January 2023, TPEx has long been engaged in enhancing ESG information transparency, including requiring listed companies to prepare Sustainability reports in accordance with GRI Standards and strengthening the disclosure of Sustainability Reporting with reference to international norms under TCFD and SASB.
TPEx has also made efforts to publish relevant information and guidelines to assist listed companies in strengthening ESG-related disclosure. The rate of listed companies that prepared sustainability reports for 2020 was around 20% and according to the "CG WATCH 2020 Report” from the Asian Corporate Governance Association (ACGA), Taiwan’s concerted effort over the past two years to enhance its CG ecosystem has moved it from fifth to fourth position.
In order to deepen sustainable growth, TPEx has strengthened the function of the board of directors for listed companies and continues to expand the scope of TPEx-listed companies that are required to prepare Sustainability reports. Companies are encouraged to enhance communications with stakeholders, and from June 2023, TPEx-listed companies will also be required to appoint a Chief Governance Officer.
To meet the needs for ESG investing and sustainable financing globally, TPEx has been promoting diversified ESG investment products and responsible investment. TPEx has launched several sustainability-themed indexes to steer market funds toward investments that address climate change and environmental sustainability. The Chairman of TPEx, Philip Chen, stated that, “TPEx commits to upholding ESG values to strengthen our core businesses. TPEx will continue to promote capital raising functionality, innovative and sustainable related products, information transparency, and efficient fair-trading mechanisms; building a vibrant and innovative world-class capital market.”
For more information about the Taipei Exchange, please visit: https://www.tpex.org.tw/web/index.php?l=en-us
View source version on businesswire.com: https://www.businesswire.com/news/home/20220608005017/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom